Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Flecainide acetate

Related Products

Hot Products

Name

Flecainide acetate

EINECS 258-997-5
CAS No. 54143-56-5 Density 1.286 g/cm3
PSA 96.89000 LogP 4.25130
Solubility Soluble in dilute acetic acid, dimethyl sulfoxide, ethanol, methanol and water. Melting Point 145-147℃
Formula C19H24F6N2O5 Boiling Point 434.9 °C at 760 mmHg
Molecular Weight 474.4 Flash Point 216.8 °C
Transport Information N/A Appearance N/A
Safety 22-26-36/37/39-45 Risk Codes 22-36/37/38-63
Molecular Structure Molecular Structure of 54143-56-5 (FLECAINIDE ACETATE) Hazard Symbols HarmfulXn
Synonyms

R-818;2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidinylmethyl)benzamide acetate;Flecainide acetate;N-(2-Piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate;54143-55-4;FLECAINIDE MONOACETATE;R 818;Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, monoacetate;Tambocor;Flecainide acetate [USAN:JAN];Benzamide,N-(2-piperidinylmethyl)-2,5-bis(2,- 2,2-trifluoroethoxy)-,monoacetate;N-(Piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide monoacetate;Tambocor (TN);acetic acid; N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide;Flecainide acetate (JAN/USP);? Flecainide acetate;

Article Data 5

Flecainide acetate Specification

The Flecainide acetate, with the CAS registry number 54143-56-5, is also known as 2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidinylmethyl)benzamide acetate. It belongs to the product category of Organics. Its EINECS registry number is 258-997-5. This chemical's molecular formula is C19H24F6N2O5 and molecular weight is 474.39. Its IUPAC name is called acetic acid; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide. This chemical's classification codes are Cardiac Depressant (anti-arrhythmic); Human Data; Reproductive Effect. Flecainide acetate is a class Ic antiarrhythmic agent used to prevent and treat tachyarrhythmias. It is used to treat a variety of cardiac arrhythmias including paroxysmal atrial fibrillation, paroxysmal supraventricular tachycardia, and ventricular tachycardia. 

Physical properties of Flecainide acetate: (1)ACD/LogP: 2.90; (2)ACD/LogD (pH 5.5): -0.19; (3)ACD/LogD (pH 7.4): 0.19; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1.76; (8)#H bond acceptors: 5; (9)#H bond donors: 2; (10)#Freely Rotating Bonds: 7; (11)Flash Point: 216.8 °C; (12)Enthalpy of Vaporization: 69.11 kJ/mol; (13)Boiling Point: 434.9 °C at 760 mmHg; (14)Vapour Pressure: 9.11E-08 mmHg at 25°C.

When you are using this chemical, please be cautious about it as the following:
This chemical may cause damage to health. It is harmful if swallowed. In addition, it is irritating to eyes, respiratory system and skin. You should not breathe its dust. Whenever you will contact it, please wear suitable protective clothing, gloves and eye/face protection. In case of accident or if you feel unwell seek medical advice immediately (show the label where possible).

You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)C.FC(F)(F)COc2cc(C(=O)NCC1NCCCC1)c(OCC(F)(F)F)cc2
(2)InChI: InChI=1/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)
(3)InChIKey: RKXNZRPQSOPPRN-UHFFFAOYAP

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 oral 50mg/kg (50mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 33, Pg. 2427, 1991.
dog LDLo unreported 15mg/kg (15mg/kg) CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 1714, 1999.
man LDLo multiple routes 25mg/kg/1W-I (25mg/kg) CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) American Journal of Cardiology. Vol. 53, Pg. 329, 1984.
man LDLo oral 22989ug/kg (22.989mg/kg) CARDIAC: OTHER CHANGES

LUNGS, THORAX, OR RESPIRATION: ACUTE PULMONARY EDEMA

KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION
Forensic Science International. Vol. 106, Pg. 115, 1999.
man TDLo intravenous 1714ug/kg/4M- (1.714mg/kg) CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) American Heart Journal. Vol. 107, Pg. 222, 1984.
man TDLo multiple routes 26mg/kg/89H-I (26mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" Postgraduate Medical Journal. Vol. 62, Pg. 61, 1986.
man TDLo oral 40mg/kg/2W-I (40mg/kg) CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP
Annals of Internal Medicine. Vol. 111, Pg. 107, 1989.
mouse LD50 intravenous 23800ug/kg (23.8mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
mouse LD50 oral 170mg/kg (170mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
mouse LD50 subcutaneous 188mg/kg (188mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
rat LD50 intravenous 16200ug/kg (16.2mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
rat LD50 oral 1346mg/kg (1346mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
rat LD50 subcutaneous 215mg/kg (215mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 22, Pg. 967, 1991.
women TDLo oral 20mg/kg (20mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
American Journal of Emergency Medicine. Vol. 16, Pg. 534, 1998.
women TDLo oral 28mg/kg/1W-I (28mg/kg) SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE British Medical Journal. Vol. 291, Pg. 450, 1985.
women TDLo oral 40mg/kg (40mg/kg) CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION
British Journal of Clinical Practice. Vol. 49, Pg. 218, 1995.
women TDLo oral 50mg/kg (50mg/kg) CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE Connectical Medicine. Vol. 54, Pg. 183, 1990.
women TDLo oral 56mg/kg/1W-I (56mg/kg) CARDIAC: OTHER CHANGES American Journal of Cardiology. Vol. 55, Pg. 1643, 1985.
women TDLo oral 76mg/kg (76mg/kg) CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP Annals of Internal Medicine. Vol. 106, Pg. 807, 1987.
women TDLo oral 160mg/kg (160mg/kg) CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)

CARDIAC: CHANGE IN RATE
Medical Journal of Australia. Vol. 155, Pg. 349, 1991.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 54143-56-5